Andrew H.S. Lee

10.0k total citations · 2 hit papers
88 papers, 7.1k citations indexed

About

Andrew H.S. Lee is a scholar working on Cancer Research, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Andrew H.S. Lee has authored 88 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Cancer Research, 54 papers in Pathology and Forensic Medicine and 42 papers in Oncology. Recurrent topics in Andrew H.S. Lee's work include Breast Cancer Treatment Studies (56 papers), Breast Lesions and Carcinomas (53 papers) and Cancer and Skin Lesions (23 papers). Andrew H.S. Lee is often cited by papers focused on Breast Cancer Treatment Studies (56 papers), Breast Lesions and Carcinomas (53 papers) and Cancer and Skin Lesions (23 papers). Andrew H.S. Lee collaborates with scholars based in United Kingdom, Egypt and United States. Andrew H.S. Lee's co-authors include Ian O. Ellis, Emad A. Rakha, Andrew R. Green, Maysa E. El‐Sayed, Desmond G. Powe, Emma C. Paish, J.F.R. Robertson, Matthew J. Grainge, Zsolt Hodi and R. Douglas Macmillan and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Andrew H.S. Lee

84 papers receiving 6.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor-Infiltrating CD8⁺Lymphocytes Predict Clinical Outcome in Breast Cancer

2011 1.1k citations Emma C. Paish, Desmond G. Powe et al. profile →
Prognostic markers in triple‐negative breast cancer

2006 1.0k citations Emad A. Rakha, Maysa E. El‐Sayed et al. Cancer profile →

Peers

Countries citing papers authored by Andrew H.S. Lee

Since Specialization

Citations

This map shows the geographic impact of Andrew H.S. Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew H.S. Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew H.S. Lee more than expected).

Fields of papers citing papers by Andrew H.S. Lee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew H.S. Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew H.S. Lee. The network helps show where Andrew H.S. Lee may publish in the future.

Co-authorship network of co-authors of Andrew H.S. Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew H.S. Lee. A scholar is included among the top collaborators of Andrew H.S. Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew H.S. Lee. Andrew H.S. Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Deciphering the Clinical Behaviour of Invasive Lobular Carcinoma of the Breast Defines an Aggressive Subtype 2024 ·Cancers ·(unknown), (unknown), Susanna Polotto, Andrew H.S. Lee, Andrew R. Green, Emad A. Rakha	5
2	Should a borderline negative HER2 result in a core biopsy of invasive carcinoma of the breast have HER2 assessment repeated in the excision specimen? 2023 ·Journal of Clinical Pathology ·Andrew H.S. Lee, Zsolt Hodi, (unknown), (unknown), Ian O. Ellis, Emad A. Rakha	1
3	Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases 2021 ·British Journal of Cancer ·Emad A. Rakha, Islam M. Miligy, Cecily Quinn, Elena Provenzano, Abeer M. Shaaban, Caterina Marchiò, Michael S. Toss, (unknown), Ciara Murray, Janice M. Walshe, Ayaka Katayama, (unknown), (unknown), Bruce Tanchel, Rebecca Millican‐Slater, Colin A. Purdie, (unknown), Sarah E. Pinder, Ian O. Ellis, Andrew H.S. Lee	13
4	Malignant phyllodes tumour of the breast mimicking endometriosis 2021 ·Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·Andrew H.S. Lee, Ulises Zanetto, (unknown), (unknown), Nur Diyana Md Nasir, Cedric Chuan Young Ng, Bin Tean Teh, Puay Hoon Tan	2
5	The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution 2019 ·British Journal of Cancer ·Islam M. Miligy, Michael S. Toss, Kylie L. Gorringe, Andrew H.S. Lee, Ian O. Ellis, Andrew R. Green, Emad A. Rakha	29
6	Interobserver variation in the diagnosis of fibroepithelial lesions of the breast: a multicentre audit by digital pathology 2018 ·Journal of Clinical Pathology ·Benjamin F. Dessauvagie, Andrew H.S. Lee, Katie Meehan, (unknown), Puay Hoon Tan, Jeremy Thomas, (unknown), Darren Treanor, (unknown), Andrew M. Hanby, Rebecca Millican‐Slater	19
7	National survey of B1 and B2 reporting of breast needle core biopsies 2015 ·Journal of Clinical Pathology ·Rahul Deb, Jacquie Jenkins, David J. Rowlands, Ian O. Ellis, Andrew H.S. Lee	1
8	Human epidermal growth factor receptor 2 testing in invasive breast cancer: should histological grade, type and oestrogen receptor status influence the decision to repeat testing? 2015 ·Histopathology ·Emad A. Rakha, (unknown), Sandra J. Shin, Timothy M. D’Alfonso, Ian O. Ellis, Andrew H.S. Lee	6
9	Pleomorphic adenoma‐like tumour of the breast 2015 ·Histopathology ·Emad A. Rakha, Mohammed A. Aleskandarany, Rehab Monir Samaka, Zsolt Hodi, Andrew H.S. Lee, Ian O. Ellis	12
10	Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer 2014 ·Clinical Cancer Research ·Tarek M. Abdel-Fatah, Graham Ball, Andrew H.S. Lee, Sarah E. Pinder, (unknown), Eleanor Cornford, Paul M. Moseley, (unknown), (unknown), (unknown), D. M. Palmer, Arlene Chan, Ian O. Ellis, Stephen Chan	14
11	The effect of delay in fixation on HER2 expression in invasive carcinoma of the breast assessed with immunohistochemistry and in situ hybridisation 2014 ·Journal of Clinical Pathology ·Andrew H.S. Lee, (unknown), (unknown), (unknown), Zsolt Hodi, Ian O. Ellis	13
12	Updated UK Recommendations for HER2 assessment in breast cancer 2014 ·Journal of Clinical Pathology ·Emad A. Rakha, Sarah E. Pinder, John M.S. Bartlett, Merdol Ibrahim, Jane Starczynski, P J Carder, Elena Provenzano, Andrew M. Hanby, S Hales, Andrew H.S. Lee, Ian O. Ellis	194
13	Breast carcinomas with borderline (2+) HER2 immunohistochemistry: percentage of cells with complete membrane staining for HER2 and the frequency of HER2 amplification: Table 1 2011 ·Journal of Clinical Pathology ·Andrew H.S. Lee, (unknown), (unknown), Zsolt Hodi, Ian O. Ellis	24
14	Lymph-node metastases in invasive lobular carcinoma are different from those in ductal carcinoma of the breast 2011 ·Journal of Clinical Pathology ·(unknown), Emma C. Paish, Andrew R. Green, Andrew H.S. Lee, R. Douglas Macmillan, Ian O. Ellis, Emad A. Rakha	47
15	Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation 2010 ·Histopathology ·T’ng Chang Kwok, Emad A. Rakha, Andrew H.S. Lee, Matthew J. Grainge, Andrew R. Green, Ian O. Ellis, Desmond G. Powe	36
16	Comparison of margin assessment by radial and shave sections in wide local excision specimens for invasive carcinoma of the breast 2010 ·Histopathology ·Zsolt Hodi, Ian O. Ellis, C.W. Elston, Sarah E. Pinder, (unknown), R. Douglas Macmillan, Andrew H.S. Lee	8
17	Prognostic markers in triple‐negative breast cancer breakdown → 2006 ·Cancer ·Emad A. Rakha, Maysa E. El‐Sayed, Andrew R. Green, Andrew H.S. Lee, J.F.R. Robertson, Ian O. Ellis	1039
18	Columnar Cell Lesions of the Breast: The Missing Link in Breast Cancer Progression? 2005 ·The American Journal of Surgical Pathology ·Peter T. Simpson, (unknown), Jorge S. Reis‐Filho, Chris Jones, Suzanne Parry, J P Sloane, Andrew M. Hanby, Sarah E. Pinder, Andrew H.S. Lee, (unknown), Ian O. Ellis, Sunil R. Lakhani	200
19	Columnar cell lesions of the breast 2005 ·The American Journal of Surgical Pathology ·Peter T. Simpson, (unknown), Jorge S. Reis‐Filho, Chris Jones, Suzanne Parry, J P Sloane, Andrew M. Hanby, Sarah E. Pinder, Andrew H.S. Lee, (unknown), Ian O. Ellis, Sunil R. Lakhani	1
20	Invasive lobular and invasive ductal carcinoma of the breast show distinct patterns of vascular endothelial growth factor expression and angiogenesis 1998 ·The Journal of Pathology ·Andrew H.S. Lee, Edwin A. Dublin, Lynda G. Bobrow, Richard Poulsom	104

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact